Study of the Effect of Eicosanoids on Contractile Activity of Pregnant Human Myometrium in Pathological Situation (EAU2)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00939744|
Recruitment Status : Unknown
Verified March 2015 by Jean-Charles Pasquier, MD, PhD, Université de Sherbrooke.
Recruitment status was: Recruiting
First Posted : July 15, 2009
Last Update Posted : March 4, 2015
Recent studies show that EET and 20-HETE have important biological effects, particularly in the vascular system. The investigators studied the effect of eicosanoids on the gravid rat uterus. The results suggest that 20-HETE had an tocolytics effect on gravid uterus. In the previous study, we demonstrated that the enzymes of the pathway of EET were present in human uterine tissues. Moreover, the addition of an inhibitor of degradation of EET had an tocolytic effect on the human myometrium, as the exogenous addition of 8.9, 14,15-EET and 20-HETE.
Primary objective: To compare the balance of different metabolic pathways of arachidonic acid (AA) of the pregnant human myometrium in pathological situations (preterm labor, uterine atony, prolonged pregnancy).
Specific objectives: i) To study the effect of derived from the AA on in vitro contractile activity of normal and pathological uterine tissues, and ii) detect and quantify the different sub-products of metabolism of AA in the uterine tissues (myometrium, fetal membranes and placenta).
The management of uterine contraction is in the heart of modern obstetrics year, yet the progress made in other specialties, based on the study of smooth muscle have not yet been transposed in obstetrics. A better understanding of systems for regulating the contraction is important in terms of 1) new physiological knowledge, but it could also be the source of 2) modification of strategies to take care of premature delivery (new Tocolytic), or 3) improving the efficiency of uterine muscle during delivery or 4) for treatment of patients with prolonged pregnancy.
|Condition or disease|
|Obstetric Labor Complications Prolonged Pregnancy|
It is a clinical study with a slope fundamental aims to examine the metabolic pathways of AA of human myometrium and their functional roles according to their clinical profile divided into three contractile pathological situations - threat of premature delivery, dynamic dystocia, prolonged pregnancy - and two groups of patients at term: a group before work and group work.
The sampling method. After birth, a biopsy will be perform from the lower segment of the uterus. After caesarean sections of membrane and placenta are collected.
The substances studied during isometric tension tests are part of the three degradation pathways of the AA.
- new eicosanoids in cumulative dose (8,9-EET, 11,12-EET, 14,15-EET, 20-HETE), and in combination
- enzyme inhibitors of the eicosanoids pathway (AUDA, MS-PPOH, DDMS), and the COX and LOX pathways (indomethacin), alone or in combination.
|Study Type :||Observational|
|Estimated Enrollment :||130 participants|
|Official Title:||Study of the Effect of Eicosanoids on Contractile Activity of Pregnant Human Myometrium in Pathological Situation.|
|Study Start Date :||May 2009|
|Estimated Primary Completion Date :||July 2015|
|Estimated Study Completion Date :||October 2015|
Women who will have a c-section at the CHUS
- effect of eicosanoids on contractile activity of myometrium of pregnant women with pathological situations [ Time Frame: during c-section ]
- effect of enzymatic inhibitors on contractile activity of myometrium from pregnant women with pathological situations [ Time Frame: during c-section ]
- detection of enzymes from the different pathways [ Time Frame: after c-section ]
- quantification of eicosanoids in different tissues [ Time Frame: after c-section ]
Biospecimen Retention: Samples Without DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00939744
|Contact: Stéphanie Corriveau, BSc||819 346-1110 ext email@example.com|
|Contact: Simon Blouin, PhD||819 346-1110 ext firstname.lastname@example.org|
|Centre hospitalier de l'Université de Sherbrooke||Recruiting|
|Sherbrooke, Quebec, Canada, J1H 5N4|
|Principal Investigator:||Jean-Charles Pasquier, MD, PhD||Centre hospitalier de l'Université de Sherbrooke|
|Principal Investigator:||Rousseau Éric, PhD||Université de Sherbrooke|